Compare PBHC & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | AVXL |
|---|---|---|
| Founded | 1859 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.9M | 115.9M |
| IPO Year | 2014 | 2013 |
| Metric | PBHC | AVXL |
|---|---|---|
| Price | $16.72 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.2K | ★ 1.3M |
| Earning Date | 11-06-2026 | 11-24-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 46.25 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $1.14 |
| 52 Week High | $18.30 | $8.79 |
| Indicator | PBHC | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 25.95 |
| Support Level | $15.48 | N/A |
| Resistance Level | $17.45 | $1.60 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 63.99 | 30.70 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.